Price List - Emcitate - Thyroid and Antithyroid Agents - NA.xlsx
XLSX spreadsheet 45 KB Posted
- Solicitation number
- HT9402-27-Q-9102
- Issued by
-
Defense Health Agency
About this file
This is a price list template for pharmaceutical quotes submitted to the Department of War (DoW) Pharmacy and Therapeutics (P&T) Committee for the Thyroid and Antithyroid Agents drug class, scheduled for review at the February 3-4, 2027 P&T Committee meeting. The quote submission deadline is November 30, 2026. The price list serves as an appendix to solicitation HT9402-27-Q-9102 and contains templates for ten newly approved drugs within the Thyroid and Antithyroid Agents classification. The document includes sections for Blanket Purchase Agreement (BPA) pricing, Additional Discount Program (ADP) pricing using both Federal Ceiling Price (FCP) methodology and Wholesale Acquisition Cost (WAC) discount methodology. Manufacturers must submit completed quote information alongside a Quote Review Checklist and fully executed signature pages.
The pricing templates require manufacturers to provide unit pricing that will apply uniformly across all package sizes (e.g., 30s, 100s, 1000s) for Military Treatment Facilities and Mail Order venues. For BPA submissions, manufacturers must indicate pricing for both Uniform Formulary and Non-Formulary scenarios. For ADP submissions under the FCP method, manufacturers must provide Non-FAMP pricing, additional offered refund percentages, and current annual Federal Ceiling Prices for Tier 2 and Tier 3 formulary categories. The WAC discount method requires manufacturers to provide WAC discount percentages that remain static throughout the agreement period. The document notes that agents without submitted quotes may be designated as non-step preferred and subject to step therapy requirements, and that the P&T Committee may recommend preferential tier placement or complete exclusion from the TRICARE pharmacy benefit program.
View the file
Other files
| File | Type | Posted |
|---|---|---|
| RFQ HT9402-27-Q-9102 NAD.pdf | ||
| Price List - Atebrioz - Skeletal Muscle Relaxants and Combinations - NA.xlsx | XLSX spreadsheet | |
| DoD Formulary Placement of FDA Newly Approved Drugs.pdf | ||
| FAR 52-225-6-Certificate.pdf | ||
| Price List - Zegfrovy - Lung Cancer - EGFR NSCLC.xlsx | XLSX spreadsheet | |
| Price List - Hibsago - Hepatitis B Agents - NA.xlsx | XLSX spreadsheet | |
| Price List - Juvmo - Parkinsons Agents - NA.xlsx | XLSX spreadsheet | |
| Price Appendix FAQ NAD.pdf |
On GovTribe
Work with this file
- Download the original file
- Contacts named in this file
- Similar government files
- Ask GovTribe AI about this file
Text version
BPA
| UF BPA NDC Price List for the February 2027 DoW P&T Meeting | |||
| DoW Uniform Formulary Class: | THYROID AND ANTITHYROID AGENTS | P&T Committee Meeting: | February 3-4, 2027 |
| DoW Uniform Formulary Subclass: | N/A | Quotes due: | November 30, 2026 |
| Formulary Notes | |||
| Class Note(s): This agent will be reviewed at the upcoming quarterly P&T Committee meeting according to 32 CFR 199.21(g)(5). Prior Authorization (PA) may apply. Agents may be identified as possible candidates for special reimbursement methods, amounts, and procedures to encourage use of high-value products and discourage use of low-value products. The P&T Committee may recommend consideration of preferential status to any non-generic pharmaceutical agent by treating it for purposes of cost sharing as a generic product (Tier 1). Similarly, the P&T Committee may identify candidates to recommend complete exclusion from the TRICARE pharmacy benefit program. |
Step Therapy Addendum: Grandfathering: a prior authorization process that allows current patients to remain on current therapy and requires new patients to complete an adequate trial of the step-preferred (before-step) agent before a non-step-preferred (after-step) agent is provided to the patient at any MTF, Retail, or Mail point of service.
Agents with RFQ not submitted or selected may be designated non-step preferred (after-step).
Notes to Manufacturers: Do not forget to submit the Quote Review Checklist and fully executed signature pages, along with quote information.
The price per unit of measure for a given dosage form and strength (each, gram, mL, etc.) of the pharmaceutical agent will be the same for all available package sizes (e.g., 30s, 100s, 1000s) within a given dispensing venue.
Blanket Purchase Agreement Appendix – Newly Approved Drug
| #1 | DoW Uniform Formulary Class: | THYROID AND ANTITHYROID AGENTS | P&T Committee Meeting: | February 3-4, 2027 | ||
| DoW Uniform Formulary Subclass: | N/A | Quotes due: | November 30, 2026 | |||
| NDC Number | Drug Name | Strength | Dosage Form | Package Size | Military Treatment Facility & Mail Order |
Formulary Scenarios Condition Set # Formulary Category Description One of (x) Number of Brand Agents Price per NDC Package Size Price per Unit
| Scenario 1 | 272TANAG1UF1M | Uniform Formulary | 1 or more | NO QUOTE | |
| 272TANAG1NF1M | Non-Formulary | 1 or more | NO QUOTE | ||
| If cell highlights red, please confirm intent not to submit a quote | |||||
| Blanket Purchase Agreement Appendix – Newly Approved Drug |
| #2 | DoW Uniform Formulary Class: | THYROID AND ANTITHYROID AGENTS | P&T Committee Meeting: | February 3-4, 2027 | ||
| DoW Uniform Formulary Subclass: | N/A | Quotes due: | November 30, 2026 | |||
| NDC Number | Drug Name | Strength | Dosage Form | Package Size | Military Treatment Facility & Mail Order |
Formulary Scenarios Condition Set # Formulary Category Description One of (x) Number of Brand Agents Price per NDC Package Size Price per Unit
| Scenario 1 | 272TANAG1UF1M | Uniform Formulary | 1 or more | NO QUOTE | |
| 272TANAG1NF1M | Non-Formulary | 1 or more | NO QUOTE | ||
| If cell highlights red, please confirm intent not to submit a quote | |||||
| Blanket Purchase Agreement Appendix – Newly Approved Drug |
| #3 | DoW Uniform Formulary Class: | THYROID AND ANTITHYROID AGENTS | P&T Committee Meeting: | February 3-4, 2027 | ||
| DoW Uniform Formulary Subclass: | N/A | Quotes due: | November 30, 2026 | |||
| NDC Number | Drug Name | Strength | Dosage Form | Package Size | Military Treatment Facility & Mail Order |
Formulary Scenarios Condition Set # Formulary Category Description One of (x) Number of Brand Agents Price per NDC Package Size Price per Unit
| Scenario 1 | 272TANAG1UF1M | Uniform Formulary | 1 or more | NO QUOTE | |
| 272TANAG1NF1M | Non-Formulary | 1 or more | NO QUOTE | ||
| If cell highlights red, please confirm intent not to submit a quote |
Blanket Purchase Agreement Appendix – Newly Approved Drug
| #4 | DoW Uniform Formulary Class: | THYROID AND ANTITHYROID AGENTS | P&T Committee Meeting: | February 3-4, 2027 | ||
| DoW Uniform Formulary Subclass: | N/A | Quotes due: | November 30, 2026 | |||
| NDC Number | Drug Name | Strength | Dosage Form | Package Size | Military Treatment Facility & Mail Order |
Formulary Scenarios Condition Set # Formulary Category Description One of (x) Number of Brand Agents Price per NDC Package Size Price per Unit
| Scenario 1 | 272TANAG1UF1M | Uniform Formulary | 1 or more | NO QUOTE | |
| 272TANAG1NF1M | Non-Formulary | 1 or more | NO QUOTE | ||
| If cell highlights red, please confirm intent not to submit a quote | |||||
| Blanket Purchase Agreement Appendix – Newly Approved Drug |
| #5 | DoW Uniform Formulary Class: | THYROID AND ANTITHYROID AGENTS | P&T Committee Meeting: | February 3-4, 2027 | ||
| DoW Uniform Formulary Subclass: | N/A | Quotes due: | November 30, 2026 | |||
| NDC Number | Drug Name | Strength | Dosage Form | Package Size | Military Treatment Facility & Mail Order |
Formulary Scenarios Condition Set # Formulary Category Description One of (x) Number of Brand Agents Price per NDC Package Size Price per Unit
| Scenario 1 | 272TANAG1UF1M | Uniform Formulary | 1 or more | NO QUOTE | |
| 272TANAG1NF1M | Non-Formulary | 1 or more | NO QUOTE | ||
| If cell highlights red, please confirm intent not to submit a quote |
Blanket Purchase Agreement Appendix – Newly Approved Drug
| #6 | DoW Uniform Formulary Class: | THYROID AND ANTITHYROID AGENTS | P&T Committee Meeting: | February 3-4, 2027 | ||
| DoW Uniform Formulary Subclass: | N/A | Quotes due: | November 30, 2026 | |||
| NDC Number | Drug Name | Strength | Dosage Form | Package Size | Military Treatment Facility & Mail Order |
Formulary Scenarios Condition Set # Formulary Category Description One of (x) Number of Brand Agents Price per NDC Package Size Price per Unit
| Scenario 1 | 272TANAG1UF1M | Uniform Formulary | 1 or more | NO QUOTE | |
| 272TANAG1NF1M | Non-Formulary | 1 or more | NO QUOTE | ||
| If cell highlights red, please confirm intent not to submit a quote |
Blanket Purchase Agreement Appendix – Newly Approved Drug
| #7 | DoW Uniform Formulary Class: | THYROID AND ANTITHYROID AGENTS | P&T Committee Meeting: | February 3-4, 2027 | ||
| DoW Uniform Formulary Subclass: | N/A | Quotes due: | November 30, 2026 | |||
| NDC Number | Drug Name | Strength | Dosage Form | Package Size | Military Treatment Facility & Mail Order |
Formulary Scenarios Condition Set # Formulary Category Description One of (x) Number of Brand Agents Price per NDC Package Size Price per Unit
| Scenario 1 | 272TANAG1UF1M | Uniform Formulary | 1 or more | NO QUOTE | |
| 272TANAG1NF1M | Non-Formulary | 1 or more | NO QUOTE | ||
| If cell highlights red, please confirm intent not to submit a quote |
Blanket Purchase Agreement Appendix – Newly Approved Drug
| #8 | DoW Uniform Formulary Class: | THYROID AND ANTITHYROID AGENTS | P&T Committee Meeting: | February 3-4, 2027 | ||
| DoW Uniform Formulary Subclass: | N/A | Quotes due: | November 30, 2026 | |||
| NDC Number | Drug Name | Strength | Dosage Form | Package Size | Military Treatment Facility & Mail Order |
Formulary Scenarios Condition Set # Formulary Category Description One of (x) Number of Brand Agents Price per NDC Package Size Price per Unit
| Scenario 1 | 272TANAG1UF1M | Uniform Formulary | 1 or more | NO QUOTE | |
| 272TANAG1NF1M | Non-Formulary | 1 or more | NO QUOTE | ||
| If cell highlights red, please confirm intent not to submit a quote | |||||
| Blanket Purchase Agreement Appendix – Newly Approved Drug |
| #9 | DoW Uniform Formulary Class: | THYROID AND ANTITHYROID AGENTS | P&T Committee Meeting: | February 3-4, 2027 | ||
| DoW Uniform Formulary Subclass: | N/A | Quotes due: | November 30, 2026 | |||
| NDC Number | Drug Name | Strength | Dosage Form | Package Size | Military Treatment Facility & Mail Order |
Formulary Scenarios Condition Set # Formulary Category Description One of (x) Number of Brand Agents Price per NDC Package Size Price per Unit
| Scenario 1 | 272TANAG1UF1M | Uniform Formulary | 1 or more | NO QUOTE | |
| 272TANAG1NF1M | Non-Formulary | 1 or more | NO QUOTE | ||
| If cell highlights red, please confirm intent not to submit a quote | |||||
| Blanket Purchase Agreement Appendix – Newly Approved Drug |
| #10 | DoW Uniform Formulary Class: | THYROID AND ANTITHYROID AGENTS | P&T Committee Meeting: | February 3-4, 2027 | ||
| DoW Uniform Formulary Subclass: | N/A | Quotes due: | November 30, 2026 | |||
| NDC Number | Drug Name | Strength | Dosage Form | Package Size | Military Treatment Facility & Mail Order |
Formulary Scenarios Condition Set # Formulary Category Description One of (x) Number of Brand Agents Price per NDC Package Size Price per Unit
| Scenario 1 | 272TANAG1UF1M | Uniform Formulary | 1 or more | NO QUOTE | |
| 272TANAG1NF1M | Non-Formulary | 1 or more | NO QUOTE | ||
| If cell highlights red, please confirm intent not to submit a quote |
&"-,Italic"Use or disclosure of data contained on this sheet is subject to the restriction on the title page of this quote.
ADP (non-FAMP Discount)
| UF ADP Appendix for the February 2027 DoW P&T Meeting | |||
| DoW Uniform Formulary Class: | THYROID AND ANTITHYROID AGENTS | P&T Committee Meeting: | February 3-4, 2027 |
| DoW Uniform Formulary Subclass: | N/A | Quotes due: | November 30, 2026 |
| Formulary Notes | |||
| Class Note(s): This agent will be reviewed at the upcoming quarterly P&T Committee meeting according to 32 CFR 199.21(g)(5). Prior Authorization (PA) may apply. Agents may be identified as possible candidates for special reimbursement methods, amounts, and procedures to encourage use of high-value products and discourage use of low-value products. The P&T Committee may recommend consideration of preferential status to any non-generic pharmaceutical agent by treating it for purposes of cost sharing as a generic product (Tier 1). Similarly, the P&T Committee may identify candidates to recommend complete exclusion from the TRICARE pharmacy benefit program. |
Step Therapy Addendum: Grandfathering: a prior authorization process that allows current patients to remain on current therapy and requires new patients to complete an adequate trial of the step-preferred (before-step) agent before a non-step-preferred (after-step) agent is provided to the patient at any MTF, Retail, or Mail point of service.
Notes to Manufacturers: Do not forget to submit the Quote Review Checklist and fully executed signature pages, along with quote information.
* Total Calculated Refund Per FCP is calculated as: ((non-FAMP-FCP)+(non-FAMP*Y%)) = Total Calculated Refund **Based on the most recent annual non-FAMP (reported to the Department of Veterans Affairs) from which the current annual Federal Ceiling Price (FCP) calculated ceiling is derived. The current annual FCP and the annual non-FAMP from which it is derived will be applicable to all prescriptions filled during a calendar year. The quoted additional refund percentage will remain static during the life of the agreement but the most recent annual non-FAMP, and thus the calculated refund, may change each calendar year.
Additional Discount Program Appendix – Newly Approved Drug
| #1 | DoW Uniform Formulary Class: | THYROID AND ANTITHYROID AGENTS | P&T Committee Meeting: | February 3-4, 2027 | |||
| DoW Uniform Formulary Subclass: | N/A | Quotes due: | November 30, 2026 | ||||
| NDC Number | Drug Name | Strength | Dosage Form | Package Size | TRICARE RETAIL REFUND |
Formulary Scenarios Condition Set # Formulary Category Description One of (x) Number of Brand Agents Non-FAMP Price of Drug Per FCP Package** Additional Offered Refund Per FCP Package** Current Annual Federal Ceiling Price Per FCP Package** Standard Refund Per FCP Total Calculated Retail Refund Per FCP Package*
| Scenario 1 | 272TANAG1T21M | Tier 2 | 1 or more | |
| 272TANAG1T31M | Tier 3 | 1 or more | ||
| If cell highlights red, please confirm intent not to submit a quote |
Additional Discount Program Appendix – Newly Approved Drug
| #2 | DoW Uniform Formulary Class: | THYROID AND ANTITHYROID AGENTS | P&T Committee Meeting: | February 3-4, 2027 | |||
| DoW Uniform Formulary Subclass: | N/A | Quotes due: | November 30, 2026 | ||||
| NDC Number | Drug Name | Strength | Dosage Form | Package Size | TRICARE RETAIL REFUND |
Formulary Scenarios Condition Set # Formulary Category Description One of (x) Number of Brand Agents Non-FAMP Price of Drug Per FCP Package** Additional Offered Refund Per FCP Package** Current Annual Federal Ceiling Price Per FCP Package** Standard Refund Per FCP Total Calculated Retail Refund Per FCP Package*
| Scenario 1 | 272TANAG1T21M | Tier 2 | 1 or more | |
| 272TANAG1T31M | Tier 3 | 1 or more | ||
| If cell highlights red, please confirm intent not to submit a quote |
Additional Discount Program Appendix – Newly Approved Drug
| #3 | DoW Uniform Formulary Class: | THYROID AND ANTITHYROID AGENTS | P&T Committee Meeting: | February 3-4, 2027 | |||
| DoW Uniform Formulary Subclass: | N/A | Quotes due: | November 30, 2026 | ||||
| NDC Number | Drug Name | Strength | Dosage Form | Package Size | TRICARE RETAIL REFUND |
Formulary Scenarios Condition Set # Formulary Category Description One of (x) Number of Brand Agents Non-FAMP Price of Drug Per FCP Package** Additional Offered Refund Per FCP Package** Current Annual Federal Ceiling Price Per FCP Package** Standard Refund Per FCP Total Calculated Retail Refund Per FCP Package*
| Scenario 1 | 272TANAG1T21M | Tier 2 | 1 or more | |
| 272TANAG1T31M | Tier 3 | 1 or more | ||
| If cell highlights red, please confirm intent not to submit a quote |
Additional Discount Program Appendix – Newly Approved Drug
| #4 | DoW Uniform Formulary Class: | THYROID AND ANTITHYROID AGENTS | P&T Committee Meeting: | February 3-4, 2027 | |||
| DoW Uniform Formulary Subclass: | N/A | Quotes due: | November 30, 2026 | ||||
| NDC Number | Drug Name | Strength | Dosage Form | Package Size | TRICARE RETAIL REFUND |
Formulary Scenarios Condition Set # Formulary Category Description One of (x) Number of Brand Agents Non-FAMP Price of Drug Per FCP Package** Additional Offered Refund Per FCP Package** Current Annual Federal Ceiling Price Per FCP Package** Standard Refund Per FCP Total Calculated Retail Refund Per FCP Package*
| Scenario 1 | 272TANAG1T21M | Tier 2 | 1 or more | |
| 272TANAG1T31M | Tier 3 | 1 or more | ||
| If cell highlights red, please confirm intent not to submit a quote | ||||
| Additional Discount Program Appendix – Newly Approved Drug |
| #5 | DoW Uniform Formulary Class: | THYROID AND ANTITHYROID AGENTS | P&T Committee Meeting: | February 3-4, 2027 | |||
| DoW Uniform Formulary Subclass: | N/A | Quotes due: | November 30, 2026 | ||||
| NDC Number | Drug Name | Strength | Dosage Form | Package Size | TRICARE RETAIL REFUND |
Formulary Scenarios Condition Set # Formulary Category Description One of (x) Number of Brand Agents Non-FAMP Price of Drug Per FCP Package** Additional Offered Refund Per FCP Package** Current Annual Federal Ceiling Price Per FCP Package** Standard Refund Per FCP Total Calculated Retail Refund Per FCP Package*
| Scenario 1 | 272TANAG1T21M | Tier 2 | 1 or more | |
| 272TANAG1T31M | Tier 3 | 1 or more | ||
| If cell highlights red, please confirm intent not to submit a quote |
Additional Discount Program Appendix – Newly Approved Drug
| #6 | DoW Uniform Formulary Class: | THYROID AND ANTITHYROID AGENTS | P&T Committee Meeting: | February 3-4, 2027 | |||
| DoW Uniform Formulary Subclass: | N/A | Quotes due: | November 30, 2026 | ||||
| NDC Number | Drug Name | Strength | Dosage Form | Package Size | TRICARE RETAIL REFUND |
Formulary Scenarios Condition Set # Formulary Category Description One of (x) Number of Brand Agents Non-FAMP Price of Drug Per FCP Package** Additional Offered Refund Per FCP Package** Current Annual Federal Ceiling Price Per FCP Package** Standard Refund Per FCP Total Calculated Retail Refund Per FCP Package*
| Scenario 1 | 272TANAG1T21M | Tier 2 | 1 or more | |
| 272TANAG1T31M | Tier 3 | 1 or more | ||
| If cell highlights red, please confirm intent not to submit a quote |
Additional Discount Program Appendix – Newly Approved Drug
| #7 | DoW Uniform Formulary Class: | THYROID AND ANTITHYROID AGENTS | P&T Committee Meeting: | February 3-4, 2027 | |||
| DoW Uniform Formulary Subclass: | N/A | Quotes due: | November 30, 2026 | ||||
| NDC Number | Drug Name | Strength | Dosage Form | Package Size | TRICARE RETAIL REFUND |
Formulary Scenarios Condition Set # Formulary Category Description One of (x) Number of Brand Agents Non-FAMP Price of Drug Per FCP Package** Additional Offered Refund Per FCP Package** Current Annual Federal Ceiling Price Per FCP Package** Standard Refund Per FCP Total Calculated Retail Refund Per FCP Package*
| Scenario 1 | 272TANAG1T21M | Tier 2 | 1 or more | |
| 272TANAG1T31M | Tier 3 | 1 or more | ||
| If cell highlights red, please confirm intent not to submit a quote |
Additional Discount Program Appendix – Newly Approved Drug
| #8 | DoW Uniform Formulary Class: | THYROID AND ANTITHYROID AGENTS | P&T Committee Meeting: | February 3-4, 2027 | |||
| DoW Uniform Formulary Subclass: | N/A | Quotes due: | November 30, 2026 | ||||
| NDC Number | Drug Name | Strength | Dosage Form | Package Size | TRICARE RETAIL REFUND |
Formulary Scenarios Condition Set # Formulary Category Description One of (x) Number of Brand Agents Non-FAMP Price of Drug Per FCP Package** Additional Offered Refund Per FCP Package** Current Annual Federal Ceiling Price Per FCP Package** Standard Refund Per FCP Total Calculated Retail Refund Per FCP Package*
| Scenario 1 | 272TANAG1T21M | Tier 2 | 1 or more | |
| 272TANAG1T31M | Tier 3 | 1 or more | ||
| If cell highlights red, please confirm intent not to submit a quote |
Additional Discount Program Appendix – Newly Approved Drug
| #9 | DoW Uniform Formulary Class: | THYROID AND ANTITHYROID AGENTS | P&T Committee Meeting: | February 3-4, 2027 | |||
| DoW Uniform Formulary Subclass: | N/A | Quotes due: | November 30, 2026 | ||||
| NDC Number | Drug Name | Strength | Dosage Form | Package Size | TRICARE RETAIL REFUND |
Formulary Scenarios Condition Set # Formulary Category Description One of (x) Number of Brand Agents Non-FAMP Price of Drug Per FCP Package** Additional Offered Refund Per FCP Package** Current Annual Federal Ceiling Price Per FCP Package** Standard Refund Per FCP Total Calculated Retail Refund Per FCP Package*
| Scenario 1 | 272TANAG1T21M | Tier 2 | 1 or more | |
| 272TANAG1T31M | Tier 3 | 1 or more | ||
| If cell highlights red, please confirm intent not to submit a quote | ||||
| Additional Discount Program Appendix – Newly Approved Drug |
| #10 | DoW Uniform Formulary Class: | THYROID AND ANTITHYROID AGENTS | P&T Committee Meeting: | February 3-4, 2027 | |||
| DoW Uniform Formulary Subclass: | N/A | Quotes due: | November 30, 2026 | ||||
| NDC Number | Drug Name | Strength | Dosage Form | Package Size | TRICARE RETAIL REFUND |
Formulary Scenarios Condition Set # Formulary Category Description One of (x) Number of Brand Agents Non-FAMP Price of Drug Per FCP Package** Additional Offered Refund Per FCP Package** Current Annual Federal Ceiling Price Per FCP Package** Standard Refund Per FCP Total Calculated Retail Refund Per FCP Package*
| Scenario 1 | 272TANAG1T21M | Tier 2 | 1 or more | |
| 272TANAG1T31M | Tier 3 | 1 or more | ||
| If cell highlights red, please confirm intent not to submit a quote |
&"-,Italic"Use or disclosure of data contained on this sheet is subject to the restriction on the title page of this quote.
ADP (WAC Discount)
| UF ADP Appendix for the February 2027 DoW P&T Meeting | |||
| DoW Uniform Formulary Class: | THYROID AND ANTITHYROID AGENTS | P&T Committee Meeting: | February 3-4, 2027 |
| DoW Uniform Formulary Subclass: | N/A | Quotes due: | November 30, 2026 |
| Formulary Notes | |||
| Class Note(s): This agent will be reviewed at the upcoming quarterly P&T Committee meeting according to 32 CFR 199.21(g)(5). Prior Authorization (PA) may apply. Agents may be identified as possible candidates for special reimbursement methods, amounts, and procedures to encourage use of high-value products and discourage use of low-value products. The P&T Committee may recommend consideration of preferential status to any non-generic pharmaceutical agent by treating it for purposes of cost sharing as a generic product (Tier 1). Similarly, the P&T Committee may identify candidates to recommend complete exclusion from the TRICARE pharmacy benefit program. |
Step Therapy Addendum: Grandfathering: a prior authorization process that allows current patients to remain on current therapy and requires new patients to complete an adequate trial of the step-preferred (before-step) agent before a non-step-preferred (after-step) agent is provided to the patient at any MTF, Retail, or Mail point of service.
Notes to Manufacturers: Do not forget to submit the Quote Review Checklist and fully executed signature pages, along with quote information.
The Wholesale Acquisition Cost (WAC) is obtained from First Databank via daily price updates; it is maintained at the dispensing unit level to five (5) decimal places. If the WAC changes during a calendar quarter, an average WAC will be calculated on a daily weighted basis (per unit only).
WAC is ONLY used for products that do not have a FCP, such as diabetic supplies (i.e., test strips), and can also be applied to covered drugs.
*The quoted WAC Discount percentage will remain static during the life of the agreement.
Additional Discount Program Appendix – Newly Approved Drug
| #1 | DoW Uniform Formulary Class: | THYROID AND ANTITHYROID AGENTS | P&T Committee Meeting: | February 3-4, 2027 | ||
| DoW Uniform Formulary Subclass: | N/A | Quotes due: | November 30, 2026 | |||
| NDC Number | Drug Name | Strength | Dosage Form | Package Size | TRICARE RETAIL REFUND |
Formulary Scenarios Condition Set # Formulary Category One of (x) Number of Brand Agents WAC Price of Drug WAC Discount* Total Calculated Retail Refund per Package
| Scenario 1 | 272TANAG1T21M | Tier 2 | 1 or more | |
| 272TANAG1T31M | Tier 3 | 1 or more | ||
| If cell highlights red, please confirm intent not to submit a quote |
Additional Discount Program Appendix – Newly Approved Drug
| #2 | DoW Uniform Formulary Class: | THYROID AND ANTITHYROID AGENTS | P&T Committee Meeting: | February 3-4, 2027 | ||
| DoW Uniform Formulary Subclass: | N/A | Quotes due: | November 30, 2026 | |||
| NDC Number | Drug Name | Strength | Dosage Form | Package Size | TRICARE RETAIL REFUND |
Formulary Scenarios Condition Set # Formulary Category One of (x) Number of Brand Agents WAC Price of Drug WAC Discount* Total Calculated Retail Refund per Package
| Scenario 1 | 272TANAG1T21M | Tier 2 | 1 or more | |
| 272TANAG1T31M | Tier 3 | 1 or more | ||
| If cell highlights red, please confirm intent not to submit a quote |
Additional Discount Program Appendix – Newly Approved Drug
| #3 | DoW Uniform Formulary Class: | THYROID AND ANTITHYROID AGENTS | P&T Committee Meeting: | February 3-4, 2027 | ||
| DoW Uniform Formulary Subclass: | N/A | Quotes due: | November 30, 2026 | |||
| NDC Number | Drug Name | Strength | Dosage Form | Package Size | TRICARE RETAIL REFUND |
Formulary Scenarios Condition Set # Formulary Category One of (x) Number of Brand Agents WAC Price of Drug WAC Discount* Total Calculated Retail Refund per Package
| Scenario 1 | 272TANAG1T21M | Tier 2 | 1 or more | |
| 272TANAG1T31M | Tier 3 | 1 or more | ||
| If cell highlights red, please confirm intent not to submit a quote |
Additional Discount Program Appendix – Newly Approved Drug
| #4 | DoW Uniform Formulary Class: | THYROID AND ANTITHYROID AGENTS | P&T Committee Meeting: | February 3-4, 2027 | ||
| DoW Uniform Formulary Subclass: | N/A | Quotes due: | November 30, 2026 | |||
| NDC Number | Drug Name | Strength | Dosage Form | Package Size | TRICARE RETAIL REFUND |
Formulary Scenarios Condition Set # Formulary Category One of (x) Number of Brand Agents WAC Price of Drug WAC Discount* Total Calculated Retail Refund per Package
| Scenario 1 | 272TANAG1T21M | Tier 2 | 1 or more | |
| 272TANAG1T31M | Tier 3 | 1 or more | ||
| If cell highlights red, please confirm intent not to submit a quote |
Additional Discount Program Appendix – Newly Approved Drug
| #5 | DoW Uniform Formulary Class: | THYROID AND ANTITHYROID AGENTS | P&T Committee Meeting: | February 3-4, 2027 | ||
| DoW Uniform Formulary Subclass: | N/A | Quotes due: | November 30, 2026 | |||
| NDC Number | Drug Name | Strength | Dosage Form | Package Size | TRICARE RETAIL REFUND |
Formulary Scenarios Condition Set # Formulary Category One of (x) Number of Brand Agents WAC Price of Drug WAC Discount* Total Calculated Retail Refund per Package
| Scenario 1 | 272TANAG1T21M | Tier 2 | 1 or more | |
| 272TANAG1T31M | Tier 3 | 1 or more | ||
| If cell highlights red, please confirm intent not to submit a quote |
Additional Discount Program Appendix – Newly Approved Drug
| #6 | DoW Uniform Formulary Class: | THYROID AND ANTITHYROID AGENTS | P&T Committee Meeting: | February 3-4, 2027 | ||
| DoW Uniform Formulary Subclass: | N/A | Quotes due: | November 30, 2026 | |||
| NDC Number | Drug Name | Strength | Dosage Form | Package Size | TRICARE RETAIL REFUND |
Formulary Scenarios Condition Set # Formulary Category One of (x) Number of Brand Agents WAC Price of Drug WAC Discount* Total Calculated Retail Refund per Package
| Scenario 1 | 272TANAG1T21M | Tier 2 | 1 or more | |
| 272TANAG1T31M | Tier 3 | 1 or more | ||
| If cell highlights red, please confirm intent not to submit a quote |
Additional Discount Program Appendix – Newly Approved Drug
| #7 | DoW Uniform Formulary Class: | THYROID AND ANTITHYROID AGENTS | P&T Committee Meeting: | February 3-4, 2027 | ||
| DoW Uniform Formulary Subclass: | N/A | Quotes due: | November 30, 2026 | |||
| NDC Number | Drug Name | Strength | Dosage Form | Package Size | TRICARE RETAIL REFUND |
Formulary Scenarios Condition Set # Formulary Category One of (x) Number of Brand Agents WAC Price of Drug WAC Discount* Total Calculated Retail Refund per Package
| Scenario 1 | 272TANAG1T21M | Tier 2 | 1 or more | |
| 272TANAG1T31M | Tier 3 | 1 or more | ||
| If cell highlights red, please confirm intent not to submit a quote |
Additional Discount Program Appendix – Newly Approved Drug
| #8 | DoW Uniform Formulary Class: | THYROID AND ANTITHYROID AGENTS | P&T Committee Meeting: | February 3-4, 2027 | ||
| DoW Uniform Formulary Subclass: | N/A | Quotes due: | November 30, 2026 | |||
| NDC Number | Drug Name | Strength | Dosage Form | Package Size | TRICARE RETAIL REFUND |
Formulary Scenarios Condition Set # Formulary Category One of (x) Number of Brand Agents WAC Price of Drug WAC Discount* Total Calculated Retail Refund per Package
| Scenario 1 | 272TANAG1T21M | Tier 2 | 1 or more | |
| 272TANAG1T31M | Tier 3 | 1 or more | ||
| If cell highlights red, please confirm intent not to submit a quote |
Additional Discount Program Appendix – Newly Approved Drug
| #9 | DoW Uniform Formulary Class: | THYROID AND ANTITHYROID AGENTS | P&T Committee Meeting: | February 3-4, 2027 | ||
| DoW Uniform Formulary Subclass: | N/A | Quotes due: | November 30, 2026 | |||
| NDC Number | Drug Name | Strength | Dosage Form | Package Size | TRICARE RETAIL REFUND |
Formulary Scenarios Condition Set # Formulary Category One of (x) Number of Brand Agents WAC Price of Drug WAC Discount* Total Calculated Retail Refund per Package
| Scenario 1 | 272TANAG1T21M | Tier 2 | 1 or more | |
| 272TANAG1T31M | Tier 3 | 1 or more | ||
| If cell highlights red, please confirm intent not to submit a quote |
Additional Discount Program Appendix – Newly Approved Drug
| #10 | DoW Uniform Formulary Class: | THYROID AND ANTITHYROID AGENTS | P&T Committee Meeting: | February 3-4, 2027 | ||
| DoW Uniform Formulary Subclass: | N/A | Quotes due: | November 30, 2026 | |||
| NDC Number | Drug Name | Strength | Dosage Form | Package Size | TRICARE RETAIL REFUND |
Formulary Scenarios Condition Set # Formulary Category One of (x) Number of Brand Agents WAC Price of Drug WAC Discount* Total Calculated Retail Refund per Package
| Scenario 1 | 272TANAG1T21M | Tier 2 | 1 or more | |
| 272TANAG1T31M | Tier 3 | 1 or more | ||
| If cell highlights red, please confirm intent not to submit a quote |
&"-,Italic"Use or disclosure of data contained on this sheet is subject to the restriction on the title page of this quote.
File details come from the government source that posted it. Updated .